A recent study published in the Chinese Journal of General Surgery concluded that pirarubicin in combination with capecitabine (AX) regimen is easier to administer, has a lower incidence of vomiting and severe vomiting, and has a better overall quality of life for patients when compared to the traditional pirarubicin in combination with cyclophosphamide (AC) regimen. The researchers registered 60 breast cancer patients on the AX regimen and 60 breast cancer patients on the AC regimen for adverse reactions and conducted a quality of life survey using the Breast Cancer Quality of Life Scale to compare the two responses. The results showed that the incidence of vomiting and severe vomiting (grade III/IV) was significantly lower in the AX regimen than in the AC regimen (53.3% vs. 75.0%); the incidence of hand-foot syndrome was significantly higher in the AX regimen than in the AC regimen, but the differences between the two groups in the incidence of severe hand-foot syndrome and the incidence of bone marrow suppression, nausea, diarrhea, hair loss, and cardiac discomfort and severe adverse reactions (grade III/IV) were not statistically significant. The quality of life functional domain survey showed that the AX regimen scored significantly higher than the AC regimen in the personal role and social function domains, and there was no statistically significant difference between the two groups in the somatic, emotional, and cognitive function scores.